샘플 요청 목록

 카트 문의
시장보고서
상품코드
1879982

세계의 내분비 검사 시장

Endocrine Testing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 168 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 내분비 검사 시장은 2030년까지 169억 달러에 달할 전망

2024년에 126억 달러로 추정되는 세계의 내분비 검사 시장은 2024-2030년의 분석 기간에 CAGR 5.0%로 성장하며, 2030년까지 169억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석 대상으로 한 부문의 하나인 탠덤 질량분석 기술은 6.3%의 CAGR을 기록하며, 분석 기간 종료시까지 53억 달러에 달할 것으로 예측됩니다. 면역측정 기술 부문의 성장률은 분석 기간에 5.0%의 CAGR로 추정되고 있습니다.

미국 시장은 33억 달러로 추정되는 한편, 중국은 7.8%의 CAGR로 성장할 것으로 예측됩니다.

미국내 분비 검사 시장은 2024년에 33억 달러로 추정되고 있습니다. 세계 2위의 경제 규모를 자랑하는 중국은 2024-2030년의 분석 기간에 CAGR 7.8%로 추이하며, 2030년까지 38억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다를 들 수 있으며, 분석 기간 중 각각 CAGR 2.6%, 4.7%로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 3.0%의 CAGR로 성장할 것으로 전망되고 있습니다.

세계의 내분비 검사 시장 - 주요 동향과 촉진요인의 개요

내분비 검사는 의료와 질병 관리를 어떻게 혁신하고 있는가?

내분비 검사는 대사, 성장, 생식, 생식 및 전신 건강 상태를 조절하는 데 매우 중요한 역할을 하는 체내 호르몬 시스템의 기능에 대한 중요한 지식을 제공함으로써 의료 및 질병 관리에 혁신을 가져오고 있습니다. 이 검사는 혈액, 소변 또는 타액 샘플을 분석하여 호르몬 수치를 측정하여 당뇨병, 갑상선 질환, 부신 기능 장애, 생식 건강 문제 등 다양한 내분비 질환을 진단, 모니터링 및 관리하는 데 도움이 될 수 있습니다. 호르몬 균형의 정확한 감지 및 모니터링은 효과적인 치료에 필수적입니다. 정상치에서 조금만 벗어나도 건강에 심각한 영향을 미칠 수 있기 때문입니다. 검사 기술의 발전으로 내분비 검사는 더욱 정밀하고, 접근하기 쉽고, 종합적인 검사로 발전하고 있습니다. 이를 통해 의료진은 더 일찍 병을 진단하고, 더 효과적으로 치료를 조정하고, 더 정확하게 경과를 모니터링할 수 있게 되었습니다. 내분비계에 대한 이해가 깊어지고 비만, 심혈관질환, 골다공증 등 만성질환과의 연관성이 밝혀지면서 내분비 검사는 예방의학 및 맞춤의료의 기초로 점점 더 중요하게 여겨지고 있습니다.

내분비 검사의 기능성을 높이는 혁신이란?

내분비 검사의 기능 향상에는 진단 기술의 발전, 자동화, 맞춤형 의료의 혁신이 기여하고 있습니다. 가장 중요한 발전 중 하나는 면역측정법, 질량분석법 등 고감도, 고특이성 측정법의 도입입니다. 이를 통해 체내 미량의 호르몬 수치까지 정확하게 정량화할 수 있게 되었습니다. 이러한 첨단 측정법은 위양성, 위음성의 발생 확률을 낮추고 보다 신뢰할 수 있는 진단 정보를 제공합니다. 내분비 검사실의 자동화도 중요한 혁신으로, 최소한의 인위적 개입으로 높은 처리량의 검체를 처리할 수 있습니다. 이를 통해 검사 프로세스가 빨라질 뿐만 아니라 인위적인 실수 가능성을 줄여 일관되고 정확한 결과를 보장합니다. 또한 내분비 검사와 맞춤형 의료 접근법의 통합은 호르몬 관련 질환의 관리 방식을 변화시키고 있습니다. 호르몬 수치 데이터와 유전적 요인, 생활습관, 환경적 요인을 결합하여 의료진은 각 환자의 고유한 요구에 맞는 맞춤형 치료 계획을 수립할 수 있으며, 이를 통해 치료 결과를 개선하고 합병증 위험을 줄일 수 있을 것으로 기대됩니다. 또한 코티솔, 갑상선자극호르몬(TSH) 등 특정 호르몬을 대상으로 한 가정용 검사 키트의 개발로 일반인들에게도 내분비 검사가 친숙해져 개인이 편리하게 자주 호르몬 수치를 모니터링할 수 있게 되었습니다. 이러한 혁신을 통해 내분비 검사는 보다 정밀하고 효율적이며 환자 중심적인 검사를 통해 내분비 질환의 진단과 관리를 개선할 수 있게 되었습니다.

내분비 검사는 질병 관리와 환자의 치료 결과에 어떤 영향을 미치는가?

내분비 검사는 호르몬 관련 질환의 조기 진단, 표적 치료, 지속적인 모니터링을 가능하게 함으로써 질병 관리와 환자의 치료 결과에 큰 영향을 미칩니다. 갑상선 기능 항진증, 당뇨병, 부신 기능 부전 등의 내분비 질환을 조기에 발견하면 적절한 시기에 개입하여 질병의 진행을 막고 심각한 합병증의 위험을 줄일 수 있습니다. 예를 들어 내분비 검사를 통해 갑상선 기능 이상을 조기에 발견하면 치료되지 않은 갑상선 질환으로 인해 발생할 수 있는 심장병, 정신건강 문제 등의 합병증을 예방할 수 있습니다. 당뇨병과 같은 만성질환 관리에서 정기적인 내분비 검사는 혈당 모니터링과 필요에 따른 치료 계획의 조정에 필수적이며, 최적의 혈당 조절을 유지하고 신경장애, 심혈관 질환 등의 합병증 예방에 기여합니다. 호르몬 수치를 정확하게 측정하고 모니터링할 수 있는 능력은 의료진이 치료를 미세 조정할 수 있게 해주고, 약물의 용량을 적절하게 조절할 수 있게 해주며, 개인별 호르몬 프로파일에 맞는 치료를 제공할 수 있게 해줍니다. 이러한 개별화된 접근 방식은 치료 효과를 높일 뿐만 아니라, 환자의 특정 필요와 라이프스타일에 맞게 치료를 조정할 수 있으며, 환자의 순응도와 만족도를 높일 수 있습니다. 내분비 검사는 내분비 질환의 관리를 위한 중요한 정보를 제공함으로써 환자의 치료 결과와 삶의 질 향상에 중요한 역할을 하고 있습니다.

내분비 검사 시장의 성장을 주도하는 동향은?

내분비 검사 시장의 성장을 주도하는 주요 동향으로는 내분비 질환의 유병률 증가, 진단 기술의 발전, 예방 의료에 대한 관심 증가 등을 들 수 있습니다. 당뇨병, 갑상선 질환, 대사증후군 등의 질환이 전 세계에서 증가함에 따라 지속적인 모니터링과 관리가 필요한 이들 질환에 대응하기 위해 정확하고 종합적인 내분비 검사에 대한 수요가 증가하고 있습니다. 고령화도 이러한 성장에 기여하고 있는데, 노년층은 호르몬 균형이 깨지고 관련 질환에 걸리기 쉽기 때문입니다. 차세대 염기서열 분석과 첨단 면역측정법 등 진단 기술의 발전으로 내분비 검사가 더욱 정확하고 효율적으로 널리 보급되어 시장 확대가 더욱 가속화되고 있습니다. 예방의학에 대한 관심이 높아진 것도 중요한 요인입니다. 호르몬 불균형을 조기에 발견하고 관리하는 것은 만성질환의 발병을 예방하고 장기적인 건강상태를 개선하는 데 매우 중요합니다. 또한 내분비 검사가 디지털 헬스 플랫폼 및 원격의료와 통합되면서 검사에 대한 접근성이 확대되고, 원격 모니터링 및 상담이 가능해졌습니다. 이는 특히 의료서비스가 부족한 지역이나 지방에 거주하는 환자들에게 도움이 될 수 있습니다. 내분비 검사를 유전자 정보 및 생활습관 데이터와 결합하여 치료를 개인화하는 '맞춤의료' 접근법의 발전도 내분비 검사가 개인 맞춤형 치료 툴로서 내분비 검사의 매력을 높여주고 있습니다. 이러한 추세는 내분비 검사가 질병 예방, 관리 및 맞춤 치료 전략의 핵심 요소로 자리 잡으면서 현대 의학에서 내분비 검사의 중요성이 커지고 있음을 보여줍니다.

부문:

검사 유형별(갑상선 자극 호르몬(TSH) 검사, 인슐린 검사, 에스트라디올, 난포자극호르몬(FSH) 검사, 기타 검사 유형별) 기술(탠덤 질량분석법, 면역측정 기술, 임상화학 기술, 모노클로널 항체·폴리클로널 항체 기술, 센서 기술, 기타 기술)

조사 대상 기업의 예

  • Agilent Technologies, Inc.
  • Apollo Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Dartmouth-Hitchcock
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • HCA Healthcare UK
  • Holston Medical Group
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics, Inc.

AI 통합

검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보를 혁신하고 있습니다.

Market Glass, Inc.는 LLM이나 산업 특화형 SLM을 쿼리하는 일반적인 방식이 아닌, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등이 포함됩니다.

관세 영향 계수

Market Glass, Inc.가 본사 소재지, 생산기지, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하는 가운데, 이번 보고서에서는 지역적 시장에 대한 관세의 영향을 반영했습니다. 이러한 복잡하고 다면적인 시장 현실은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 경쟁사에게 다양한 영향을 미치며, 미시적 및 거시적 시장 역학에도 영향을 미칩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.12.09

Global Endocrine Testing Market to Reach US$16.9 Billion by 2030

The global market for Endocrine Testing estimated at US$12.6 Billion in the year 2024, is expected to reach US$16.9 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Tandem Mass Spectrometry Technology, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Immunoassay Technology segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.3 Billion While China is Forecast to Grow at 7.8% CAGR

The Endocrine Testing market in the U.S. is estimated at US$3.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Endocrine Testing Market - Key Trends and Drivers Summarized

How Is Endocrine Testing Revolutionizing Healthcare and Disease Management?

Endocrine testing is revolutionizing healthcare and disease management by providing critical insights into the functioning of the body’s hormonal system, which plays a vital role in regulating metabolism, growth, reproduction, and overall well-being. This type of testing involves analyzing blood, urine, or saliva samples to measure hormone levels, which can help diagnose, monitor, and manage various endocrine disorders, such as diabetes, thyroid diseases, adrenal insufficiencies, and reproductive health issues. The accurate detection and monitoring of hormone imbalances are essential for effective treatment, as even small deviations from normal levels can significantly impact a person’s health. With advancements in testing technologies, endocrine testing has become more precise, accessible, and comprehensive, allowing healthcare providers to diagnose conditions earlier, tailor treatments more effectively, and monitor progress with greater accuracy. As the understanding of the endocrine system deepens and its link to chronic diseases like obesity, cardiovascular diseases, and osteoporosis becomes clearer, endocrine testing is increasingly seen as a cornerstone of preventive and personalized medicine.

What Innovations Are Enhancing the Functionality of Endocrine Testing?

Innovations in endocrine testing are enhancing its functionality through advancements in diagnostic technologies, automation, and personalized medicine. One of the most significant developments is the introduction of highly sensitive and specific assays, such as immunoassays and mass spectrometry, which allow for the accurate quantification of even minute hormone levels in the body. These advanced assays reduce the likelihood of false positives and negatives, providing more reliable diagnostic information. Automation in endocrine testing labs is another key innovation, enabling high-throughput processing of samples with minimal human intervention. This not only speeds up the testing process but also reduces the potential for human error, ensuring consistent and accurate results. Additionally, the integration of endocrine testing with personalized medicine approaches is transforming the way hormone-related conditions are managed. By combining hormone level data with genetic, lifestyle, and environmental factors, healthcare providers can create tailored treatment plans that address the unique needs of each patient, improving outcomes and reducing the risk of complications. Furthermore, the development of at-home testing kits for certain hormones, such as cortisol or thyroid-stimulating hormone (TSH), is making endocrine testing more accessible to the general public, allowing individuals to monitor their hormone levels conveniently and frequently. These innovations are making endocrine testing more precise, efficient, and patient-centered, driving improvements in the diagnosis and management of endocrine disorders.

How Does Endocrine Testing Impact Disease Management and Patient Outcomes?

Endocrine testing has a profound impact on disease management and patient outcomes by enabling early diagnosis, targeted treatment, and ongoing monitoring of hormone-related conditions. Early detection of endocrine disorders, such as hyperthyroidism, diabetes, or adrenal insufficiency, allows for timely intervention, which can prevent the progression of the disease and reduce the risk of severe complications. For example, identifying thyroid dysfunction early through endocrine testing can prevent complications like heart disease or mental health issues that may arise from untreated thyroid disorders. In managing chronic conditions like diabetes, regular endocrine testing is essential for monitoring blood glucose levels and adjusting treatment plans as needed, helping to maintain optimal blood sugar control and prevent complications such as neuropathy or cardiovascular disease. The ability to measure and monitor hormone levels accurately also allows healthcare providers to fine-tune treatments, ensuring that medications are dosed correctly and that therapies are tailored to the individual’s hormonal profile. This personalized approach not only improves the effectiveness of treatment but also enhances patient compliance and satisfaction, as treatments are more likely to align with the patient’s specific needs and lifestyle. By providing critical information that guides the management of endocrine disorders, endocrine testing plays a vital role in improving patient outcomes and quality of life.

What Trends Are Driving Growth in the Endocrine Testing Market?

Several trends are driving growth in the endocrine testing market, including the rising prevalence of endocrine disorders, advancements in diagnostic technologies, and the increasing focus on preventive healthcare. The global rise in conditions such as diabetes, thyroid disorders, and metabolic syndromes is fueling demand for accurate and comprehensive endocrine testing, as these conditions require ongoing monitoring and management. The aging population is also contributing to this growth, as older adults are more susceptible to hormone imbalances and related diseases. Advancements in diagnostic technologies, such as next-generation sequencing and advanced immunoassays, are making endocrine testing more accurate, efficient, and widely available, further driving market expansion. The growing emphasis on preventive healthcare is another key factor, as early detection and management of hormone imbalances are critical in preventing the onset of chronic diseases and improving long-term health outcomes. Additionally, the integration of endocrine testing with digital health platforms and telemedicine is expanding access to these tests, allowing for remote monitoring and consultation, which is particularly beneficial for patients in underserved or rural areas. The development of personalized medicine approaches, which combine endocrine testing with genetic and lifestyle data to tailor treatments, is also enhancing the appeal of endocrine testing as a tool for individualized care. These trends highlight the increasing importance of endocrine testing in modern healthcare, as it becomes a central component of disease prevention, management, and personalized treatment strategies.

SCOPE OF STUDY:

The report analyzes the Endocrine Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing, Other Test Types); Technology (Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology, Other Technologies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 31 Featured) -

  • Agilent Technologies, Inc.
  • Apollo Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Dartmouth-Hitchcock
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • HCA Healthcare UK
  • Holston Medical Group
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Endocrine Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Prevalence of Endocrine Disorders Driving Demand for Testing
    • Technological Advancements in Diagnostic Tests Enhancing Accuracy and Speed
    • Integration of Telehealth and Remote Testing Options Expanding Accessibility
    • Impact of Lifestyle Diseases on the Growing Need for Endocrine Testing
    • Developments in Biomarker Discovery and Its Application in Endocrine Disorders
    • Future Outlook: AI Integration in Diagnostic Workflows for Endocrine Disorders
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Insulin Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Estradiol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Immunoassay Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Clinical Chemistry Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Monoclonal & Polyclonal Antibody Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Sensors Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 34: World Endocrine Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • JAPAN
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • CHINA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • EUROPE
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • GERMANY
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Spain 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Spain 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Russia 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Russia 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of Europe 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Australia 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Australia 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • INDIA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: India 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: India 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: South Korea 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: South Korea 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Latin America 15-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Argentina 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Argentina 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Brazil 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Brazil 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Mexico 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Mexico 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Latin America 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Middle East 15-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Iran 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Iran 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Israel 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Israel 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Saudi Arabia 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: UAE 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: UAE 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Middle East 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030
  • AFRICA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Africa 15-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Africa 15-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제